
Scot Niglio, MD
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
Conditions I Treat
- Genitourinary cancers and conditions
- Gallbladder cancer
- Kidney (renal cell) cancer and conditions
My Specialties
- Clinical trials
- Immunotherapy
- Targeted therapy
Get to Know Me
I am a genitourinary medical oncologist who diagnoses and treats genitourinary cancers. This includes:
- Bladder cancer
- Kidney cancer (renal cell cancer)
- Testicular cancer (germ cell tumors)
- Prostate cancer
I specialize in urothelial carcinoma which are cancers that originate in the bladder, urethra, ureter, and renal pelvis. I also have extensive experience in treating rare genitourinary cancers.
I see patients at the David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center and at Memorial Sloan Kettering Westchester locations.
At Memorial Sloan Kettering Cancer Center (MSK), our team-based approach to treatment means each person’s cancer care is seen from numerous angles. We work closely with other specialists, including surgeons and radiation oncologists. When appropriate, we offer people the opportunity to participate in clinical trials.
Read more
My interest in cancer care developed early. I grew up in a cancer cluster where a higher-than-expected rate of childhood cancer cases forced a temporary shutoff of water to area schools. Chemicals buried by a dye company years earlier may have leached into the town’s well water. Living through that experience motivated me to learn more about environmental protections and cancer research.
My father’s own bladder cancer diagnosis while I was in residency played a big role in my decision to specialize in genitourinary oncology. My personal experience taught me that communicating with patients and families during the entire process is a crucial part of providing seamless cancer care. People cannot be expected to remember everything in one sitting, so in the beginning, I break things up over multiple visits. I go over information multiple times, and I am happy to take questions that come up after people leave the office.
My research focus is to develop new treatments for these cancers which include immunotherapy. I have numerous articles in peer-reviewed publications, and I have been part of many clinical trials researching treatments for bladder and urinary tract cancers.
I received a National Institutes of Health Director’s Award for my work as part of the phase 1 team that developed an immunotherapy combination that is now approved by the U.S. Food and Drug Administration (FDA) as a first-line therapy for advanced kidney cancer.
A genitourinary (jeh-nih-toh-YOOR-ih-nayr-ee) medical oncologist is a cancer doctor who specializes in genitourinary (GU) cancers. This includes bladder, kidney, penis, prostate, and testicular cancers.
- Assistant Attending Physician
Conditions I Treat
- Genitourinary cancers and conditions
- Gallbladder cancer
- Kidney (renal cell) cancer and conditions
- Testicular cancer
- Prostate cancer and conditions
My Specialties
- Clinical trials
- Immunotherapy
- Targeted therapy
Education
- BS in Biology, Villanova University
- MS in Physiology, Georgetown University
- MS in Clinical and Translational Science, University of Medicine and Dentistry of New Jersey Graduate School of Biomedical Sciences
- MD, University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School
Residencies
- Internal Medicine, Icahn School of Medicine at Mount Sinai
Fellowships
- Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
Board Certifications
- Internal Medicine
- Medical Oncology
Awards and Honors
- National Institutes of Health Director’s Award, National Institutes of Health (2021)
- Young Investigator Award, Conquer Cancer Foundation (2019)
- 40 under 40 in Cancer, Lynx Group (2019)
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
HMO
City Employee Health Plans (Gold and Gold Care)
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment

Contact and Location
Dr. Niglio sees patients at two locations.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials
- Clinical Trials Investigated by Dr. Niglio
- A Pilot Study Assessing Immunotherapy with Nivolumab Alone or with Ipilimumab Before Surgery for Patients with Muscle-invasive Bladder Cancer Who Cannot Have Cisplatin-Based Chemotherapy

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
- Apolo AB, Ballman KV, Sonpavde G, Berg S, Kim WY, Parikh R, Teo MY, Sweis RF, Geynisman DM, Grivas P, Chatta G, Reichert ZR, Kim JW, Bilen MA, McGregor B, Singh P, Tripathi A, Cole S, Simon N, Niglio S, Ley L, Cordes L, Srinivas S, Huang J, Odegaard M, Watt C, Petrylak D, Hoffman-Censits J, Wen Y, Hahn O, Mitchell C, Tan A, Streicher H, Sharon E, Moon H, Woods M, Halabi S, Perez Burbano G, Morris MJ, Rosenberg JE. Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2025 Jan 2;392(1):45-55. doi: 10.1056/NEJMoa2401726. Epub 2024 Sep 15. PMID: 39282902; PMCID: PMC11698643.
- Niglio SA, Purswani JM, Schiff PB, Lischalk JW, Huang WC, Murray KS, Apolo AB. Organ preservation in muscle-invasive urothelial bladder cancer. Curr Opin Oncol. 2024 May 1;36(3):155-163. doi: 10.1097/CCO.0000000000001038. Epub 2024 Mar 8. PMID: 38573204.
- Apolo AB, Girardi DM, Niglio SA, Nadal R, Kydd AR, Simon N, Ley L, Cordes LM, Chandran E, Steinberg SM, Lee S, Lee MJ, Rastogi S, Sato N, Cao L, Banday AR, Boudjadi S, Merino MJ, Toubaji A, Akbulut D, Redd B, Bagheri H, Costello R, Gurram S, Agarwal PK, Chalfin HJ, Valera V, Streicher H, Wright JJ, Sharon E, Figg WD, Parnes HL, Gulley JL, Saraiya B, Pal SK, Quinn D, Stein MN, Lara PN, Bottaro DP, Mortazavi A. Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors. J Clin Oncol. 2024 Sep 1;42(25):3033-3046. doi: 10.1200/JCO.23.02233. Epub 2024 Jul 2. PMID: 38954785; PMCID: PMC11361361.,
- Necchi A, Roumiguié M, Kamat AM, Shore ND, Boormans JL, Esen AA, Lebret T, Kandori S, Bajorin DF, Krieger LEM, Niglio SA, Uchio EM, Seo HK, de Wit R, Singer EA, Grivas P, Nishiyama H, Li H, Baranwal P, Van den Sigtenhorst-Fijlstra M, Kapadia E, Kulkarni GS. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2024 Jun;25(6):720-730. doi: 10.1016/S1470-2045(24)00178-5. Epub 2024 May 10. PMID: 38740030.,
- Niglio SA, Jia R, Ji J, Ruder S, Patel VG, Martini A, Sfakianos JP, Marqueen KE, Waingankar N, Mehrazin R, Wiklund P, Oh WK, Mazumdar M, Ferket BS, Galsky MD. Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2019 Dec;76(6):782-789. doi: 10.1016/j.eururo.2019.05.037. Epub 2019 Jun 11. PMID: 31200951.
Visit PubMed for a full listing of Dr. Niglio’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.